TYME Technologies Inc
- Home
- United States
- Bedminster, NJ
- TYME Technologies Inc
TYME is delivering scientific solutions without compromise.
Address
Bedminster, NJ
Opening Hours
Monday | 9am - 5pm |
Tuesday | 9am - 5pm |
Wednesday | 9am - 5pm |
Thursday | 9am - 5pm |
Friday | 9am - 5pm |
Telephone
Website
Alerts
Be the first to know and let us send you an email when TYME Technologies Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Practice
Send a message to TYME Technologies Inc:
Shortcuts
TYME to conquer advanced cancers
TYME Technologies Inc., is an emerging biotechnology company focused on exploring novel therapeutic approaches designed to target cancer’s unique metabolism. Our mission at TYME is to develop innovative, transformational therapies that create better overall outcomes for patients and reduce the burden on healthcare resources.
While cancer survival rates have improved steadily since the 1970s, much more progress is needed. This year alone, cancer will strike nearly 1.8 million Americans and an estimated 18.1 million people worldwide. And because close to 610,000 people in the United States, and nearly 9.6 million worldwide are expected to die of cancer this year, TYME and its employees are working relentlessly to discover, develop and deliver innovative disease-altering medicines. Our goal is to transform certain advanced and difficult-to-treat cancers into diseases that are either curable or that can be managed as chronic conditions so that cancer patients can lead longer and better-quality lives.
Today, many cancers are treated with complex regimens and supportive care that are burdensome to the healthcare system and often difficult for patients to endure. At TYME, we are applying the latest advances in the field of cancer metabolism to develop novel Cancer Metabolism-Based Therapies (CMBTs™) that target the mechanisms of disease at their source, and thereby create significantly improved outcomes for patients.